MetaCap

Anika Therapeutics (ANIK) vs Profound Medical (PROF)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Anika Therapeutics (ANIK) has outperformed Profound Medical (PROF) over the past year, gaining 33.9% versus a gain of 6.2%. Over five years, PROF leads with a -43.6% price change compared with -66.6% for ANIK. Profound Medical is the larger company by market cap ($233.7 million vs $177.2 million), about 1.3 times the size.

Anika Therapeutics converts more of its revenue into profit, with a net margin of -9.6% versus -264.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIK+33.91%PROF+6.16%
+130%+54%-23%
Nov 21, 20251 yearNov 20, 2026
ANIK-66.98%PROF-47.62%
+27%-29%-85%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIK versus PROF key metrics
MetricANIKPROF
Share price$13.23$6.38
Market cap$177.22M$233.68M
1-day change-0.38%-3.19%
YTD return+37.67%-18.93%
1-year return+33.91%+6.16%
5-year return-66.63%-43.64%
Forward P/E13.23—
EPS (TTM)$-0.03$-0.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$112.82M$16.10M
Revenue growth (YoY)-5.91%+50.73%
Net income (latest FY)$-10.88M$-42.57M
Gross margin56.56%70.77%
Operating margin-9.80%-256.27%
Net margin-9.64%-264.44%
52-week high$22.88$8.95
52-week low$9.01$4.80
Distance from 52-week high-42.18%-28.72%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+51.17%+74.61%
Average volume105.68K208.29K
Shares outstanding13.40M36.63M
Employees235162
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANIK has outperformed PROF by 27.8 percentage points over the past year.
  • Anika Therapeutics is more profitable, keeping -9.6 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
  • Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs -5.91%).

About Anika Therapeutics

ANIK stock →

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.

Health Care · Medical/Dental Instruments · 235 employees

About Profound Medical

PROF stock →

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.

Health Care · Medical/Dental Instruments · 162 employees

ANIK vs PROF FAQ

Which is bigger, Anika Therapeutics or Profound Medical?

Profound Medical (PROF) is larger, with a market capitalization of $233.68M compared with $177.22M for Anika Therapeutics (ANIK).

Which stock has performed better over the past year, ANIK or PROF?

ANIK returned +33.91% over the past 12 months, compared with +6.16% for PROF (price return, excluding dividends). Past performance does not predict future results.

Are Anika Therapeutics and Profound Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons